New Two-in-One vaccine tested to shield seniors from common respiratory viruses
NCT ID NCT06583031
Summary
This first-in-human study tested the safety and immune response of a new vaccine designed to protect against two common respiratory viruses, RSV and hMPV, in adults aged 60 to 75. 385 participants received a single injection of either the combined vaccine or an RSV-only vaccine and were followed for about 6 months. The main goal was to check for side effects and see if the vaccine triggered a protective antibody response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site # 031001
Brookvale, New South Wales, 2100, Australia
-
Site # 0361002
Wollongong, New South Wales, 2500, Australia
-
Site # 0361003
Herston, Queensland, 4006, Australia
-
Site # 0361004
Botany, New South Wales, 2019, Australia
-
Site # 0361005
South Brisbane, Queensland, 4101, Australia
-
Site # 0361006
Miranda, New South Wales, 2228, Australia
Conditions
Explore the condition pages connected to this study.